JAK3 Inhibitor
JAK3 Inhibitor Basic information
- Product Name:
- JAK3 Inhibitor
- Synonyms:
-
- JAK3 Inhibitor
- 2-Bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenol
- Phenol, 2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]-
- 4-(3'-Bromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline WHI-P 154
- 2-Bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenol
- JAK3 Inhibitor II - CAS 211555-04-3 - Calbiochem
- CS-1516
- whi-p154cas
- CAS:
- 211555-04-3
- MF:
- C16H14BrN3O3
- MW:
- 376.2
- EINECS:
- 809-014-9
- Product Categories:
-
- Inhibitors
- Inhibitor
- JAK/STAT
- JAK
- STAT
- Mol File:
- 211555-04-3.mol
JAK3 Inhibitor Chemical Properties
- Melting point:
- 230 °C
- Boiling point:
- 470.3±45.0 °C(Predicted)
- Density
- 1.576±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- DMSO: soluble1mg/mL, clear (warmed)
- pka
- 8.57±0.31(Predicted)
- form
- powder
- color
- white to brown
- InChIKey
- CBIAKDAYHRWZCU-UHFFFAOYSA-N
- CAS DataBase Reference
- 211555-04-3
Safety Information
- Hazard Codes
- Xn
- Risk Statements
- 22-36/37/38
- Safety Statements
- 26
- RIDADR
- UN 2811 6.1 / PGIII
- WGK Germany
- 3
- HS Code
- 2933.59.8000
JAK3 Inhibitor Usage And Synthesis
Description
WHI-
Uses
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM and also inhibits EGFR with IC50 of 4 nM.
Uses
WHI-P154 can act as antileukemic agent with apoptosis inducing activity.
Biochem/physiol Actions
WHI-P154 is a specific inhibitor of JAK3 (IC50 = 1.8 μM) with no inhibitory activity against JAK1 or JAK2. WHI-P154 enhances myogenic differentiation of C2C12 mouse myoblast cells, and induces differentiation of neural progenitor cells. The compound WHI-P154 dose dependently inhibits expression of iNOS and NO production in LPS-challenged macrophages.
in vitro
kinase assays show that whi-p154 is not a specific inhibitor. besides jak3, it also inhibits many other kinases, including egfr, abl, lck, src and vegfr. whi-p154 inhibits egfr with ic50 value of 4nm. the specificity of whi-p154 has not been shown in cell-based assays either [1].
storage
Store at RT
References
[1] changelian ps, moshinsky d, kuhn cf, flanagan me, munchhof mj, harris tm, whipple da, doty jl, sun j, kent cr, magnuson ks, perregaux dg, sawyer ps, kudlacz em. the specificity of jak3 kinase inhibitors. blood. 2008 feb 15;111(4):2155-7.
[2] narla rk, liu xp, myers de, uckun fm. 4-(3'-bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. clin cancer res. 1998 jun;4(6):1405-14.
JAK3 InhibitorSupplier
- Tel
- 17317130613
- 3358272972@qq.com
- Tel
- sales@boylechem.com
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 0330-2528181
- sales@vdmbio.com
JAK3 Inhibitor(211555-04-3)Related Product Information
- JAK3 INHIBITOR I
- 4-(3'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE, HCL
- 2-Bromopropane
- 1-Bromo-3-methylbutane
- 2-Methylsulfonyl-4,6-dimethoxypyrimidine
- WHI-P97
- 4-PHENYLAMINO-6,7-DIMETHOXYQUINAZOLINE
- Phenol, 3-[(6,7-diMethoxy-4-quinazolinyl)aMino]-
- Tofacitinib citrate
- Stattic
- (+)-JQ1
- ABT-199
- ABT 737
- Entinostat